EU/3/15/1516: Orphan designation for the treatment of pancreatic cancer

Modified adenovirus serotype 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand and full length 4-1BBL

Overview

On 28 July 2015, orphan designation (EU/3/15/1516) was granted by the European Commission to Lokon Pharma AB, Sweden, for modified adenovirus serotype 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand and full length 4-1BBL for the treatment of pancreatic cancer.

The sponsor’s address was updated in June 2020.

Key facts

Active substance
Modified adenovirus serotype 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand and full length 4-1BBL
Intended use
Treatment of pancreatic cancer
Orphan designation status
Positive
EU designation number
EU/3/15/1516
Date of designation
28/07/2015
Sponsor

Lokon Pharma AB
Bredgrand 14
Uppsala Domkyrkofors.
Uppsala 753 20
Uppsala Lan
Sweden
Tel: +46735377161
E-mail: angelica.loskog@nxt2b.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating